Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center

PURPOSE: The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of utilization, tolerance, and outcomes with pomalid...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondili, Suresh Kumar, Bagal, Bhausaheb, Zawar, Abhinav, Ventrapati, Pradeep, Thorat, Jayashree, Gokarn, Anant, Punatar, Sachin, Nayak, Lingaraj, Bonda, Avinash, Jain, Hashmukh, Sengar, Manju, Khattry, Navin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081531/
https://www.ncbi.nlm.nih.gov/pubmed/33689483
http://dx.doi.org/10.1200/GO.20.00228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081531/
https://www.ncbi.nlm.nih.gov/pubmed/33689483
http://dx.doi.org/10.1200/GO.20.00228

Ejemplares similares